← All Chromadex CORP filings

Chromadex CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

CDXC
Chromadex CORP
10-K: Niagen Bioscience Reports Strong 2025 Growth, Strategic Shifts
Niagen Bioscience, Inc. reported significant revenue and net income growth in 2025, driven by strong Tru Niagen and ingredient sales, alongside strategic intellectual property and segment divestiture actions.
CDXC
Chromadex CORP
10-K: ChromaDex Reports Profitable 2024, Driven by Strong Growth in Consumer Products and Ingredients Segments
ChromaDex Corporation reports a profitable 2024, driven by a 19% increase in net sales, primarily from its Consumer Products and Ingredients segments.
CDXC
Chromadex CORP
10-K: ChromaDex Amends Lease, Files Annual Report, and Updates Incentive Compensation Policy
ChromaDex Corporation amends a lease for office space, files its annual report on Form 10-K, and updates its incentive compensation recoupment policy.